A Feasibility Study for the DAISe EZ Thrombectomy Device - Pacific

Sponsor

MIVI Neuroscience, Inc. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT06042335

Collaborator

(none)

Enrollment

Arm

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 20 subjects. A maximum of 5 investigational centers in Australia will participate. Enrollment is expected to take about 4 months, subject participation will last about 3 months.

Condition or Disease	Intervention/Treatment	Phase
Acute Ischemic Stroke	Device: DAISe EZ	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Feasibility Study for the DAISe EZ Thrombectomy Device - Pacific

Anticipated Study Start Date :

Dec 1, 2023

Anticipated Primary Completion Date :

Apr 1, 2024

Anticipated Study Completion Date :

Jul 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: DAISe EZ Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.	Device: DAISe EZ DAISe Thrombectomy System for mechanical thrombectomy

Arm

Intervention/Treatment

Experimental: DAISe EZ

Mechanical thrombectomy utilizing the DAISe Thrombectomy System, consisting of the DAISe Thrombectomy Device and DAISe Delivery Catheter, used with aspiration.

Device: DAISe EZ

DAISe Thrombectomy System for mechanical thrombectomy

Outcome Measures

Primary Outcome Measures

Successful revascularization [Procedure]
Defined as proportion of subjects with mTICI 2b-3 flow post treatment with the DAISe Thrombectomy Device.
Symptomatic intracranial hemorrhage (sICH) at 24 hours post-procedure [12-36 hours]
Defined as proportion of subjects with Symptomatic intracranial haemorrhage (sICH) at 24 hours post-procedure as detected by CT/MRI with clinical deterioration of an NIHSS change of greater than or equal to 4.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

1. Age 18 years or older. 2. Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Rankin Score 0-2.

Diagnosis of acute ischemic stroke with study enrollment time < 24 hours from onset of symptoms.
Disabling stroke defined as a baseline NIHSS > 6. 5. Confirmed symptomatic, large vessel occlusion of the intracranial internal carotid artery (ICA), MCA-M1 or MCA-M2.
The following imaging criteria must also be met:

For subjects 0-6hrs onset:
MRI criterion: volume of diffusion restriction as assessed by automated core volume software ≤50 mL OR
CT criterion: ASPECTS 6 to 10 on baseline CT or CTA-source images or, computed tomography perfusion (CPT) core as assessed by automated core volume software ≤50 mL.
For subjects 6-24hrs onset:
≤20mL ischemic core volume if age >80
≤30mL ischemic core volume if age <80 and NIHSS 10-20
The following imaging criteria must also be met:
≤50mL ischemic core volume if age <80 and NIHSS >20 7. Signed informed consent from patient or legal representative

Exclusion Criteria:

Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage on presentation.
Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.
Rapidly improving neurological deficits based on the investigator's clinical judgement.
Pregnancy; if a woman is of child-bearing potential and urine or serum beta HCG test is positive.
Severe contrast allergy or absolute contraindication to iodinated contrast.
Difficult endovascular access, difficult aortic arch or severe neurovascular tortuosity that will result in an inability to deliver endovascular therapy.
Evidence of dissection in the carotid or target artery for treatment.
Presence of a carotid artery stenosis or occlusion requiring balloon angioplasty or stenting at time of the procedure.
Renal failure (on dialysis).
Severe, sustained hypertension resistant to treatment (SBP >185 mmHg or DBP >110 mmHg).
Use of warfarin anticoagulation with International Normalized Ratio (INR) > 3.0 at the time of the procedure or any known hemorrhagic or coagulation deficiency.
Use of a direct thrombin inhibitor within the last 48 hours; partial thromboplastin time (PTT) > 2.0 times the normal prior to procedure.
Cerebral vasculitis or evidence of active systemic infection.
Suspicion of aortic dissection, presumed septic embolus or suspicion of bacterial endocarditis.
Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).
A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

MIVI Neuroscience, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

MIVI Neuroscience, Inc.

ClinicalTrials.gov Identifier:

NCT06042335

Other Study ID Numbers:

102699

First Posted:

Sep 18, 2023

Last Update Posted:

Sep 18, 2023

Last Verified:

Sep 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Yes

Product Manufactured in and Exported from the U.S.:

Yes

Additional relevant MeSH terms:

Ischemic Stroke

Study Results

No Results Posted as of Sep 18, 2023